ClinicalTrials.gg
RecruitingNCT06778603ROLN-B7-H3Updated Jan 16, 2025

B7-H3 NIR Imaging for Osteosarcoma Surgery

A Phase 1/2 interventional study of a targeted probe B7H3-IRDye800CW in Osteosarcoma, Resection Margins and B7-H3 Probe, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Peking University People's Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Jan 2024, registered Jan 2025).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Osteosarcoma by Peking University People's Hospital — 5 open to participants now, 7 under way, none of them phase 3. Osteosarcoma · Peking University People's Hospital.

Planned enrollment
11th of 12
32 · median 56
Started
2024
with 2 others
Phase 1/2
3 of 26
2 open now
Registered
24th of 26
by date

Among the 26 studies in Osteosarcoma by Peking University People's Hospital, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 1/2, and was the 24th registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

5 of the 26 studies in Osteosarcoma by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Osteosarcoma by Peking University People's Hospital, or all of them as a file.
02

Study summary

Complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (OS). However, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and blurry tumor boundaries. Besides, intraoperative frozen-section analysis of resection margins of OS is often restricted by the hard tissues around OS, which makes it impossible to know whether a negative margin is achieved. Herein, based on the high expression of B7-H3 in OS, a targeted probe B7H3-IRDye800CW is synthesized by conjugating anti-B7H3 antibody and IRDye800CW. This trial is aimed to investigate R0-resection rate and 2-y local recurrence rate after using this probe in Musculoskeletal tumor surgery for osteosarcoma as well as the safety parameters of this probe in human.

03

Conditions studied

  • Osteosarcoma
  • Resection Margins
  • B7-H3 Probe
  • Local Recurrence

Keywords

  • osteosarcoma
  • resection margins
  • B7-H3 Targeted Probe
  • local recurrence rate
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Patients with confirmed osteosarcoma of the limbs.
    1. the patients has not undergone tumor resection.
    1. Age between 18 and 60 years old.
    1. No prior systemic treatment for osteosarcoma.
    1. as assessed by imaging studies (e.g., MRI, CT).
    1. Adequate bone marrow, liver, and renal function.
    1. Written obtained from the patient.

Exclusion criteria

Exclusion Criteria:

    1. History of other within the past 5 years.
    1. Pregnancy or lactation.
    1. Known to any component of the B7H3-based NIR imaging agent.
    1. Uncontrolled intercurrent illness that would preclude safe study participation.
    1. Prior radiation therapy to the target lesion.
    1. Any medical condition that would compromise the patient's ability to undergo surgery or comply with study procedures.
  • 7.Patients not able to sign the .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    experimental group

    Drug: a targeted probe B7H3-IRDye800CW

Interventions

  • Druga targeted probe B7H3-IRDye800CW

    B7H3-IRDye800CW was synthesized by conjugating IRDye800CW NHS Ester and Anti-B7H3 antibody.

06

What researchers measure

Primary outcomes

  1. Safety

    According to CTCAE 5.0

    Time frame: 21 days

07

Study locations

1 of 1 sites recruiting
  • Musculoskeletal Tumor Center
    Beijing, Beijing 100044, China
    Recruiting
    • Xiaodong Tang/ Musculoskeletal Tumor Center, M.D. · Contacttang15877@126.com · +86-88326150
08

References and documents

Publications

  • Zeng F, Li C, Wang H, Wang Y, Ren T, He F, Jiang J, Xu J, Wang B, Wu Y, Yu Y, Hu Z, Tian J, Wang S, Tang X. Intraoperative Resection Guidance and Rapid Pathological Diagnosis of Osteosarcoma using B7H3 Targeted Probe under NIR-II Fluorescence Imaging. Adv Sci (Weinh). 2024 Sep;11(33):e2310167. doi: 10.1002/advs.202310167. Epub 2024 Mar 19. PubMed 38502871 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2025, 17 months after the start.

Of 33 phase 1/2 interventional studies under Osteosarcoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 92. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2025
First posted
Jan 16, 2025
StartActual
Jan 1, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Dec 31, 2026
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06778603
Collaborators
Simcere Pharmaceutical Group Limited
Responsible party
Xie Lu (Musculoskeletal Tumor Center, Peking University People's Hospital) — Principal investigator
First posted
Jan 16, 2025
Start date
Jan 1, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 16, 2025

Study contacts

Xiaodong Musculoskeletal Tumor Center of PKUPH, M.D.
Contact
tang15877@126.com
+86-88326150

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion